Wei Boon Yap

Dr. Wei Boon Yap

Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ZZZarina Mohd Zawawi
Zarina Mohd Zawawi
JKJeevanathan Kalyanasundram
Jeevanathan Kalyanasundram
RZRozainanee Mohd Zain
Rozainanee Mohd Zain
RTRavindran Thayan
Ravindran Thayan
DBDayang Fredalina Basri
Dayang Fredalina Basri
WYWei Boon Yap
Wei Boon Yap
The coronavirus disease 2019 (COVID-19) became a worldwide concern at the beginning of 2020 and has affected millions. Several previous studies revealed the impact of the imbalanced innate immune response on the progression of COVID-19 and its disease outcomes. High levels of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins are produced readily by innate immune cells to fight Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infections. Nonetheless, cytokine-mediated inflammatory events are also linked to detrimental lung injury and respiratory failure, which can result in deaths among COVID-19 patients. TNF-α is amongst the early cytokines produced to mediate proinflammatory responses and enhance immune cell infiltration in response to SARS-CoV-2 infections. In COVID-19, TNF-α-mediated inflammation can cause detrimental tissue damage and gradually promotes lung fibrosis, which later results in pneumonia, pulmonary edema, and acute respiratory distress syndrome. This review, therefore, aims to deliberate the immunomodulatory roles of TNF-α in promoting inflammation and its relation with COVID-19 morbidity and mortality. In addition, this review also proposes the potential of TNF-α as a biomarker for the prognosis of severe COVID-19 and its related complications and as a molecular target for anti-TNF-α therapy.

2 June 2018 in Food Science & Nutrition
Verified
Journal Article
Open access
PDF file
AAAsmariah Ahmad
Asmariah Ahmad
WYWei Boon Yap
Wei Boon Yap
NKNoorhisham Tan Kofli
Noorhisham Tan Kofli
AGAhmad Rohi Bin Ghazali
Ahmad Rohi Bin Ghazali
Lactic acid bacterium isolated from fermented durian (tempoyak) was investigated for its potentials as a probiotic strain. Bacterial tolerance toward gastrointestinal environment, adhesion, and cytotoxic activity in human colon adenocarcinoma cell line HT‐29 was evaluated. 16S rRNA sequencing identified the lactic acid bacterium as Lactobacillus plantarum. The bacterium demonstrated good tolerance toward gastrointestinal pH 2.0 and 0.3% bile salts. It showed strong adhesive capacity in human intestinal cell line, HT‐29, with an adhesion index of 159 ± 10. Cytotoxicity of L. plantarum was investigated using both live bacterial cells (BC) and cell‐free supernatant (CFS). Findings showed that both BC and CFS of L. plantarum reduced proliferation of HT‐29 colon adenocarcinoma cells using MTT assay. The results imply potential probiotic properties of L. plantarum isolated from tempoyak.

1 October 2008 in Biotechnology and Bioprocess Engineering
Verified
Journal Article
Closed access
PDF file
CHChin Woi Ho
Chin Woi Ho
WTWen Siang Tan
Wen Siang Tan
WYWei Boon Yap
Wei Boon Yap
TLTau Chuan Ling
Tau Chuan Ling
BTBeng Ti Tey
Beng Ti Tey

19 September 2019 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
MJMalina Jasamai
Malina Jasamai
WYWei Boon Yap
Wei Boon Yap
ASAurapa Sakulpanich
Aurapa Sakulpanich
AJAzmath Jaleel
Azmath Jaleel
Currently, treatments for dengue infection are only symptomatic as no antiviral agents nor vaccines are available to combat this virus. Despite challenges faced by researchers, many efforts are ongoing to reduce cases of dengue infection either by targeting the vector or the virus. Vector population is monitored and reduced by using mechanical, chemical and biological controls. Chemical control is achieved either by using synthetic or natural insecticides where the latter is more preferable. In biological control, bacteria, fungi and larvivorous fish are utilised to reduce the vector population. Moreover, genes of mosquitoes are also explored to produce progenies which are sterile with low survival ability. Vaccines are among the most effective ways to prevent viral infection. Various approaches have been used and are still being explored towards producing vaccines for dengue. These include live attenuated, inactivated, recombinant subunit, nucleic acid and virus-like particles vaccines. The aim is to produce a vaccine which can target all the four serotypes of the virus. Monoclonal antibodies are widely researched on to equip the host defense mechanism against the dengue virus. Deeper understanding of the virus replication cycle warrants the development of antiviral agents which target viral proteins vital for the replication process. Bioactive compounds are also utilised in the development of antiviral agents. The importance of surveillance and supportive therapy are also discussed.

1 May 2010 in Journal of Chromatography A
Verified
Journal Article
Closed access
WYWei Boon Yap
Wei Boon Yap
BTBeng Ti Tey
Beng Ti Tey
NANoorjahan Banu Mohamed Alitheen
Noorjahan Banu Mohamed Alitheen
WTWen Siang Tan
Wen Siang Tan

30 April 2020 in Malaysian Journal of Medical Sciences
Verified
Journal Article
Open access
SRSyazwani Romeli
Syazwani Romeli
SHSharifah Syed Hassan
Sharifah Syed Hassan
WYWei Boon Yap
Wei Boon Yap
In light of the limited protection conferred by current influenza vaccines, immunisation using universal influenza vaccines has been proposed for protection against all or most influenza sub-types. The fundamental principle of universal influenza vaccines is based on conserved antigens found in most influenza strains, such as matrix 2, nucleocapsid, matrix 1 and stem of hemagglutinin proteins. These antigens trigger cross-protective immunity against different influenza strains. Many researchers have attempted to produce the conserved epitopes of these antigens in the form of peptides in the hope of generating universal influenza vaccine candidates that can broadly induce cross-reactive protection against influenza viral infections. However, peptide vaccines are poorly immunogenic when applied individually owing to their small molecular sizes. Hence, strategies, such as combining peptides as multi-epitope vaccines or presenting peptides on vaccinia virus particles, are employed. This review discusses the clinical and laboratory findings of several multi-epitope peptide vaccine candidates and vaccinia-based peptide vaccines. The majority of these vaccine candidates have reached the clinical trial phase. The findings in this study will indeed shed light on the applicability of universal influenza vaccines to prevent seasonal and pandemic influenza outbreaks in the near future.